The Novartis plant in Torre Annunziata is getting bigger. The pharmaceutical company is focusing on the South and Italy with investments of 350 million euros by 2025, 70 million of which are earmarked for the expansion of the Campania site. The new investments will have a positive impact on the growth of production volumes, with an estimate for 2024 of 8.1 billion tablets and a 2025 target of approximately ten billion tablets with the production of new drugs. By 2024, production will reach more than 150 million packs, destined for 118 countries. The plant currently produces 15 brands in more than 1,600 different presentations. The site produces Novartis' most innovative heart failure drug for major international markets, starting with the United States and China. Pharmaceutical exports from the Campania region increased more than fivefold between 2018 and 2023: +475 percent. In Italy, it exceeded 49 billion euros in 2023. This is the highest figure ever, with growth of nearly 3 percent over 2022 and nearly 90 percent in the past five years.
|